Cargando…

Children and caregiver proxy quality of life from peanut oral immunotherapy trials

BACKGROUND: Health‐related quality of life (HRQoL) is significantly and substantially reduced in individuals with peanut allergy due to many factors associated with unanticipated or potentially fatal reactions. Further insight on the impact of peanut oral immunotherapy in managing peanut allergy on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galvin, Audrey Dunn, Vereda, Andrea, del Río, Pablo Rodríguez, Muraro, Antonella, Jones, Carla, Ryan, Robert, Norval, David, Jobrack, Jennifer, Anagnostou, Aikaterini, Wang, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762119/ https://www.ncbi.nlm.nih.gov/pubmed/36573312 http://dx.doi.org/10.1002/clt2.12213

Ejemplares similares

Allergy to Peanuts imPacting Emotions And Life (APPEAL): The impact of peanut allergy on children, teenagers, adults and caregivers in the UK and Ireland
por: Tsoumani, Marina, et al.
Publicado: (2022)

Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
por: Fernandez‐Rivas, Montserrat, et al.
Publicado: (2021)

APPEAL‐2: A pan‐European qualitative study to explore the burden of peanut‐allergic children, teenagers and their caregivers
por: DunnGalvin, Audrey, et al.
Publicado: (2020)

Peanut immunotherapy
por: Anagnostou, Katherine, et al.
Publicado: (2014)

Allergy to Peanuts imPacting Emotions And Life (APPEAL): the impact of peanut allergy on children, adolescents, adults and caregivers in France
por: Couratier, Pascale, et al.
Publicado: (2020)

A Practical, Stepwise Approach to Peanut Oral Immunotherapy in Clinical Practice: Benefits and Risks
por: Anagnostou, Aikaterini
Publicado: (2021)

Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials
por: Blumchen, Katharina, et al.
Publicado: (2023)

Identification of goals and barriers to treatment from 92 consecutive consultations with families considering peanut oral immunotherapy
por: Blackman, Andrea C., et al.
Publicado: (2019)

APPEAL‐1: A multiple‐country European survey assessing the psychosocial impact of peanut allergy
por: DunnGalvin, Audrey, et al.
Publicado: (2020)

Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study)
por: Chebar Lozinsky, Adriana, et al.
Publicado: (2020)

A 24‐h helpline for patients undergoing oral food immunotherapy: Lessons from Italian experience during the SARS‐CoV‐2 pandemic
por: Polloni, Laura, et al.
Publicado: (2023)

Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy
por: Anvari, Sara, et al.
Publicado: (2022)

Should peanut allergy screening be introduced for all Irish children?
por: Kelleher, Maeve, et al.
Publicado: (2015)

Insights into Microbiome and Metabolic Signatures of Children Undergoing Peanut Oral Immunotherapy
por: Blackman, Andrea C., et al.
Publicado: (2022)

Qualitative interviews to understand health care providers’ experiences of prescribing licensed peanut oral immunotherapy
por: Anagnostou, Aikaterini, et al.
Publicado: (2022)

Psychosocial and productivity impact of caring for a child with peanut allergy
por: Acaster, Sarah, et al.
Publicado: (2020)

A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy
por: Sharma, Vibha, et al.
Publicado: (2020)

Peanut Immunotherapy: Stepping Towards Desensitization for Peanut Allergy
por: Hsu, Joyce
Publicado: (2020)

Oral immunotherapy for peanut allergy: The con argument
por: Fiocchi, Alessandro, et al.
Publicado: (2020)

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
por: Fleischer, David M., et al.
Publicado: (2015)

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
por: Fleischer, David M., et al.
Publicado: (2015)

Incidence of anaphylaxis and accidental peanut exposure: A systematic review
por: Muraro, Antonella, et al.
Publicado: (2021)

Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018)

Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials
por: Lloyd, Melanie, et al.
Publicado: (2022)

Oral immunotherapy for peanut allergy: The pro argument
por: Chinthrajah, R. Sharon, et al.
Publicado: (2020)

Peanut Oral Immunotherapy: a Current Perspective
por: Patrawala, Meera, et al.
Publicado: (2020)

Peanut allergy: Beyond the oral immunotherapy plateau
por: Bruton, Kelly, et al.
Publicado: (2021)

Interpreting success or failure of peanut oral immunotherapy
por: Cao, Shijie, et al.
Publicado: (2022)

Transitioning peanut oral immunotherapy to clinical practice
por: Lazizi, S., et al.
Publicado: (2022)

Transitioning from epicutaneous to oral peanut immunotherapy
por: Wong, Lauren, et al.
Publicado: (2023)

Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities
por: Davis, Carla M., et al.
Publicado: (2022)

T cell specific and non specific tolerance mechanisms in peanut oil immunotherapy in peanut allergic subjects
por: Singh, Amit, et al.
Publicado: (2011)

A novel peanut allergoid is safe and effective in immunotherapy in a peanut allergy mouse model
por: Smit, J, et al.
Publicado: (2013)

Agreement between older adult patient and caregiver proxy symptom reports
por: Kroenke, Kurt, et al.
Publicado: (2022)

Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
por: Filipovic, Aleksandra, et al.
Publicado: (2020)

Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers
por: Gallop, Katy, et al.
Publicado: (2022)

Peanut oral immunotherapy: current trends in clinical trials
por: Reinwald, Simone, et al.
Publicado: (2022)

Allergen immunotherapy for food allergy: Evidence and outlook
por: Muraro, Antonella, et al.
Publicado: (2022)

Peanut oral immunotherapy may improve health‐related quality of life among severe peanut allergic adolescents
por: Ödling, Maria, et al.
Publicado: (2023)

The Peanut Allergy Burden Study: Impact on the quality of life of patients and caregivers
por: Nowak-Wegrzyn, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2c4kuvn7kpbgg32go9d05nh34s